Related Experiment Video
Updated: Apr 28, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
Published on: December 13, 2017
Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
1Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, 3801 University Street, # 111, Montreal, Quebec, Canada, H3A 2B4; Experimental Therapeutics Program, Montreal Neurological Institute, McGill University, 3801 University Street, # 111, Montreal, Quebec, Canada, H3A 2B4; Clinical Research Unit, Montreal Neurological Institute, McGill University, 3801 University Street, # 111, Montreal, Quebec, Canada, H3A 2B4.
Abstract:
Teriflunomide (Aubagio®) is a once-daily oral immunomodulatory disease modifying therapy (DMT) presently approved in several regions, including Europe, North America, Latin America and Australia, for the treatment of relapsing forms of multiple sclerosis (RMS; RRMS). The therapeutic mode of action of teriflunomide in MS continues to be investigated. This review summarizes the main efficacy and safety results of the clinical trial program leading to teriflunomide's approval, highlights a number of practical clinical considerations, and overviews its presumed therapeutic mode of action (MOA) based on pharmacokinetic and pharmacodynamic observations and the growing body of teriflunomide-related in vitro, pre-clinical (animal model), and in vivo human studies.
Related Concept Videos
Multiple Sclerosis l: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inhibitors of Viral Protein Synthesis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD

